Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
This is a 24-month, observational, prospective, multinational, multicenter study to determine
 the relationship between the relapse (percentage of relapse free subjects) and adherence in
 subjects diagnosed with RRMS treated with Rebif (interferon beta-1a) using the RebiSmart®2.0
 and MSdialog™.
Inclusion Criteria:

 -  Diagnosed with RRMS according to McDonald criteria 2010

 -  Relapse free within 30 days before Baseline data collection

 -  Treatment with Rebif for 6 months or more prior to informed consent

 -  Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments
 (at least once prior to informed consent)

 -  Females of childbearing potential must be willing to use appropriate contraception for
 the duration of the study

 -  EDSS score less than (<) 6

 -  Written informed consent obtained prior to any protocol-required data collection

 Exclusion Criteria:

 -  Participation in other studies within 30 days before Baseline

 -  Female who is pregnant or breast feeding

 -  Significant psychiatric symptoms that, in the opinion of the Investigator, would
 impact subject ability to comply with treatment (as per standard clinical practice)

 -  Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product
 Characteristics (SPC)

 -  Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6
 months prior to informed consent